332 related articles for article (PubMed ID: 16260268)
1. Value of estrogen and progesterone receptor immunostaining in distinguishing between peritoneal mesotheliomas and serous carcinomas.
Ordóñez NG
Hum Pathol; 2005 Nov; 36(11):1163-7. PubMed ID: 16260268
[TBL] [Abstract][Full Text] [Related]
2. h-caldesmon, calretinin, estrogen receptor, and Ber-EP4: a useful combination of immunohistochemical markers for differentiating epithelioid peritoneal mesothelioma from serous papillary carcinoma of the ovary.
Comin CE; Saieva C; Messerini L
Am J Surg Pathol; 2007 Aug; 31(8):1139-48. PubMed ID: 17667535
[TBL] [Abstract][Full Text] [Related]
3. Value of immunohistochemistry in distinguishing peritoneal mesothelioma from serous carcinoma of the ovary and peritoneum: a review and update.
Ordóñez NG
Adv Anat Pathol; 2006 Jan; 13(1):16-25. PubMed ID: 16462153
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical analysis of peritoneal mesothelioma and primary and secondary serous carcinoma of the peritoneum: antibodies to estrogen and progesterone receptors are useful.
Barnetson RJ; Burnett RA; Downie I; Harper CM; Roberts F
Am J Clin Pathol; 2006 Jan; 125(1):67-76. PubMed ID: 16482993
[TBL] [Abstract][Full Text] [Related]
5. Value of PAX8, PAX2, claudin-4, and h-caldesmon immunostaining in distinguishing peritoneal epithelioid mesotheliomas from serous carcinomas.
Ordóñez NG
Mod Pathol; 2013 Apr; 26(4):553-62. PubMed ID: 23196794
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study.
Høgdall EV; Christensen L; Høgdall CK; Blaakaer J; Gayther S; Jacobs IJ; Christensen IJ; Kjaer SK
Oncol Rep; 2007 Nov; 18(5):1051-9. PubMed ID: 17914554
[TBL] [Abstract][Full Text] [Related]
7. Role of immunohistochemistry in distinguishing epithelial peritoneal mesotheliomas from peritoneal and ovarian serous carcinomas.
Ordóñez NG
Am J Surg Pathol; 1998 Oct; 22(10):1203-14. PubMed ID: 9777982
[TBL] [Abstract][Full Text] [Related]
8. The diagnostic utility of immunohistochemistry and electron microscopy in distinguishing between peritoneal mesotheliomas and serous carcinomas: a comparative study.
Ordóñez NG
Mod Pathol; 2006 Jan; 19(1):34-48. PubMed ID: 16056246
[TBL] [Abstract][Full Text] [Related]
9. Value of mesothelial and epithelial antibodies in distinguishing diffuse peritoneal mesothelioma in females from serous papillary carcinoma of the ovary and peritoneum.
Attanoos RL; Webb R; Dojcinov SD; Gibbs AR
Histopathology; 2002 Mar; 40(3):237-44. PubMed ID: 11895489
[TBL] [Abstract][Full Text] [Related]
10. PAX8 reliably distinguishes ovarian serous tumors from malignant mesothelioma.
Laury AR; Hornick JL; Perets R; Krane JF; Corson J; Drapkin R; Hirsch MS
Am J Surg Pathol; 2010 May; 34(5):627-35. PubMed ID: 20414098
[TBL] [Abstract][Full Text] [Related]
11. A useful antibody panel for differential diagnosis between peritoneal mesothelioma and ovarian serous carcinoma in Japanese cases.
Takeshima Y; Amatya VJ; Kushitani K; Inai K
Am J Clin Pathol; 2008 Nov; 130(5):771-9. PubMed ID: 18854270
[TBL] [Abstract][Full Text] [Related]
12. Papillary serous carcinoma of peritoneum: case study and review of the literature on the differential diagnosis of malignant peritoneal tumors.
Koutselini HA; Lazaris AC; Thomopoulou G; Papayannopoulou A; Kairi-Vasilatou E
Adv Clin Path; 2001 Jul; 5(3):99-104. PubMed ID: 11753882
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic significance of carcinoembryonic antigen in the differential diagnosis of malignant mesothelioma.
Mezger J; Lamerz R; Permanetter W
J Thorac Cardiovasc Surg; 1990 Dec; 100(6):860-6. PubMed ID: 2147220
[TBL] [Abstract][Full Text] [Related]
14. Expression of HER2/neu, estrogen and progesterone receptors, CA 125 and CA19-9 on cancer cell membrane in patients with serous and mucinous carcinoma of the ovary.
Karaferic A; Jovanovic D; Jelic S
J BUON; 2009; 14(4):635-9. PubMed ID: 20148455
[TBL] [Abstract][Full Text] [Related]
15. Value of mesothelin immunostaining in the diagnosis of mesothelioma.
Ordóñez NG
Mod Pathol; 2003 Mar; 16(3):192-7. PubMed ID: 12640097
[TBL] [Abstract][Full Text] [Related]
16. Metastatic carcinomas in the cervix mimicking primary cervical adenocarcinoma and adenocarcinoma in situ: report of a series of cases.
McCluggage WG; Hurrell DP; Kennedy K
Am J Surg Pathol; 2010 May; 34(5):735-41. PubMed ID: 20414103
[TBL] [Abstract][Full Text] [Related]
17. Cytopathology of serous neoplasia of the ovary and the peritoneum: differential diagnosis from mesothelial proliferations.
Pisharodi LR; Bedrossian CW
Diagn Cytopathol; 1996 Nov; 15(4):292-5. PubMed ID: 8982583
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic and prognostic role of the insulin growth factor pathway members insulin-like growth factor-II and insulin-like growth factor binding protein-3 in serous effusions.
Slipicevic A; Øy GF; Askildt IC; Holth A; Hellesylt E; Flørenes VA; Davidson B
Hum Pathol; 2009 Apr; 40(4):527-37. PubMed ID: 19121847
[TBL] [Abstract][Full Text] [Related]
19. Peritoneal malignant mesothelioma (PMM), and primary peritoneal serous carcinoma (PPSC) and reactive mesothelial hyperplasia (RMH) of the peritoneum. Immunohistochemical and fluorescence in situ hybridisation (FISH) analyses.
Kawai T; Tominaga S; Hiroi S; Ogata S; Nakanishi K; Kawahara K; Sonobe H; Hiroshima K
J Clin Pathol; 2016 Aug; 69(8):706-12. PubMed ID: 26729015
[TBL] [Abstract][Full Text] [Related]
20. Hobnail-like cells in serous borderline tumor do not represent concomitant incipient clear cell neoplasms.
Ohishi Y; Oda Y; Kurihara S; Kaku T; Yasunaga M; Nishimura I; Okuma E; Kobayashi H; Wake N; Tsuneyoshi M
Hum Pathol; 2009 Aug; 40(8):1168-75. PubMed ID: 19368953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]